How effective is Pluvicto in a ‘real-world’ setting?
AuntMinnie
SEPTEMBER 20, 2024
Pluvicto (lutetium-177 [Lu-177] prostate-specific membrane antigen [PSMA]-617) appears to perform as effectively in prostate cancer patients in “real-world” settings as it did in clinical trials prior to its approval, according to clinicians at the Johns Hopkins Theranostics Center in Baltimore, MD. A group led by Andrei Gafita, MD, also found that an AI algorithm called SelectPSMA may help determine how patients respond to Pluvicto treatment.
Let's personalize your content